

Supplementary Table 1. Stratified analysis for associations between diabetes and clinical outcomes

Variable	p-value for interaction ^a		
	End-stage kidney disease	Cardiovascular hospitalization	Death
Age (yr), <50/≥50	0.740	0.790	0.250
Sex, female/male	0.180	0.010	0.340
Ischemic heart disease, no/yes	0.420	0.910	0.980
eGFR (mL/min/1.73 m ²), ≥60/<60	0.110	0.050	0.970
UPCR (g/g), <3/≥3	0.006	0.460	0.470
ACEi or ARB, no/yes	0.940	0.170	0.280
Immunosuppressant, no/yes	0.350	0.420	0.740

ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; UPCR, urine protein-to-creatinine ratio.

ap-value of interaction for effect modification was obtained by putting the interaction term (diabetes*variable) in the regression model.